Oramed Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, has enrolled the first patient in its glucose clamp study. The study will be performed at the University of Texas Health Science Center at San Antonio and University Health System's Texas Diabetes Institute under the supervision of Professor Ralph DeFronzo.

The glucose clamp is a method for quantifying insulin absorption in order to measure a patient's insulin sensitivity and how well a patient metabolizes glucose. The glucose clamp technique represents the gold standard for pharmacodynamic studies in diabetes drug development.

In addition to the clamp study, Oramed plans to initiate its phase IIb oral insulin trial in the U.S. with a protocol which includes over 30 U.S. sites covering approximately 180 patients and has both efficacy and safety as its primary end-points.